Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Overall Survival Data Confirm Benefit of Pembro in TNBC
BARCELONA, Spain — Long-awaited overall survival data from the KEYNOTE-522 trial has lifted spirits in the triple-negative breast cancer (TNBC) community. The trial confirmed the survival benefit of adding perioperative pembrolizumab to standard chemotherapy in stage II or III disease.…
English